Home LiteratureArticle Details
PMID: 21293058 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma.

The Journal of clinical investigation ·Vol. 121 ·No. 2 ·2011-02-00 ·Pages 809-20

Ory B, Ramsey MR, Wilson C, Vadysirisack DD, Forster N, Rocco JW, Rothenberg SM, Ellisen LW

Abstract

The p53 tumor suppressor, a central mediator of chemosensitivity in normal cells, is functionally inactivated in many human cancers. Therefore, a central challenge in human cancer therapy is the identification of pathways that control tumor cell survival and chemosensitivity in the absence of functional p53. The p53-related transcription factors p63 and p73 exhibit distinct functions—p73 mediates chemosensitivity while p63 promotes proliferation and cell survival—and are both overexpressed in squamous cell carcinomas (SCCs). However, how p63 and p73 interact functionally and govern the balance between prosurvival and proapoptotic programs in SCC remains elusive. Here, we identify a microRNA-dependent mechanism of p63/p73 crosstalk that regulates p53-independent survival of both human and murine SCC. We first discovered that a subset of p63-regulated microRNAs target p73 for inhibition. One of these, miR-193a-5p, expression of which was repressed by p63, was activated by proapoptotic p73 isoforms in both normal cells and tumor cells in vivo. Chemotherapy caused p63/p73-dependent induction of this microRNA, thereby limiting chemosensitivity due to microRNA-mediated feedback inhibition of p73. Importantly, inhibiting miR-193a interrupted this feedback and thereby suppressed tumor cell viability and induced dramatic chemosensitivity both in vitro and in vivo. Thus, we have identified a direct, microRNA-dependent regulatory circuit mediating inducible chemoresistance, whose inhibition may provide a new therapeutic opportunity in p53-deficient tumors.

MeSH Terms
Animals Antineoplastic Agents/therapeutic use Carcinoma, Squamous Cell/drug therapy,genetics,metabolism,pathology Cell Line Cell Survival DNA-Binding Proteins/genetics,metabolism Drug Resistance, Neoplasm Humans Mice Mice, Inbred C57BL Mice, Knockout MicroRNAs/genetics,metabolism Nuclear Proteins/genetics,metabolism Phosphoproteins/genetics,metabolism Signal Transduction/physiology Trans-Activators/genetics,metabolism Transcription Factors Tumor Protein p73 Tumor Suppressor Protein p53/genetics,metabolism Tumor Suppressor Proteins/genetics,metabolism
Chemicals
Antineoplastic Agents DNA-Binding Proteins MicroRNAs Nuclear Proteins Phosphoproteins TP63 protein, human TP73 protein, human Trans-Activators Transcription Factors Trp63 protein, mouse Trp73 protein, mouse Tumor Protein p73 Tumor Suppressor Protein p53 Tumor Suppressor Proteins
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Ory Benjamin
Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts 02114, USA.
Ramsey Matthew R
Wilson Catherine
Vadysirisack Douangsone D
Forster Nicole
Rocco James W
Rothenberg S Michael
Ellisen Leif W
References (50)
50 references, click to expand
  1. VISTA: computational tools for comparative genomics.
    Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W273-9 PMID: 15215394
  2. p63 and p73 in human cancer: defining the network.
    Oncogene. 2007 Aug 9;26(36):5169-83 PMID: 17334395
  3. LKB1 deficiency sensitizes mice to carcinogen-induced tumorigenesis.
    Cancer Res. 2008 Jan 1;68(1):55-63 PMID: 18172296
  4. PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells.
    Oncogene. 2009 Jun 18;28(24):2348-57 PMID: 19421143
  5. Tumor-specific p73 up-regulation mediates p63 dependence in squamous cell carcinoma.
    Cancer Res. 2006 Oct 1;66(19):9362-8 PMID: 17018588
  6. Oncogenes induce and activate endogenous p73 protein.
    J Biol Chem. 2001 Apr 6;276(14):11310-6 PMID: 11115495
  7. Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expression.
    Cancer Chemother Pharmacol. 2008 May;61(6):965-71 PMID: 17639392
  8. miRBase: tools for microRNA genomics.
    Nucleic Acids Res. 2008 Jan;36(Database issue):D154-8 PMID: 17991681
  9. Locked nucleoside analogues expand the potential of DNAzymes to cleave structured RNA targets.
    BMC Mol Biol. 2006 Jun 05;7:19 PMID: 16753066
  10. TAp73 knockout shows genomic instability with infertility and tumor suppressor functions.
    Genes Dev. 2008 Oct 1;22(19):2677-91 PMID: 18805989
  11. Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts.
    Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):11003-8 PMID: 16835297
  12. Endogenous p63 acts as a survival factor for tumour cells of SCCHN origin.
    Int J Mol Med. 2005 Dec;16(6):1065-70 PMID: 16273287
  13. Stxbp4 regulates DeltaNp63 stability by suppression of RACK1-dependent degradation.
    Mol Cell Biol. 2009 Jul;29(14):3953-63 PMID: 19451233
  14. Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics.
    Mol Cell Biol. 2000 Feb;20(4):1436-47 PMID: 10648628
  15. Human MicroRNA targets.
    PLoS Biol. 2004 Nov;2(11):e363 PMID: 15502875
  16. Therapeutic prospects for p73 and p63: rising from the shadow of p53.
    Drug Resist Updat. 2008 Aug-Oct;11(4-5):152-63 PMID: 18801697
  17. The magical touch: genome targeting in epidermal stem cells induced by tamoxifen application to mouse skin.
    Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8551-6 PMID: 10411913
  18. p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis.
    Cancer Cell. 2006 Jan;9(1):45-56 PMID: 16413471
  19. TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma.
    J Clin Oncol. 2010 Feb 10;28(5):761-6 PMID: 20048189
  20. Chemosensitivity linked to p73 function.
    Cancer Cell. 2003 Apr;3(4):403-10 PMID: 12726865
  21. p63 is a p53 homologue required for limb and epidermal morphogenesis.
    Nature. 1999 Apr 22;398(6729):708-13 PMID: 10227293
  22. Loss of p53 expression correlates with metastatic phenotype and transcriptional profile in a new mouse model of head and neck cancer.
    Mol Cancer Res. 2007 Apr;5(4):351-62 PMID: 17426250
  23. The microRNA.org resource: targets and expression.
    Nucleic Acids Res. 2008 Jan;36(Database issue):D149-53 PMID: 18158296
  24. p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2.
    Genes Dev. 2004 Dec 15;18(24):3041-54 PMID: 15601819
  25. The common and distinct target genes of the p53 family transcription factors.
    Cell Mol Life Sci. 2004 Apr;61(7-8):822-42 PMID: 15095006
  26. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis.
    Mol Cell. 2007 Jun 8;26(5):745-52 PMID: 17540599
  27. Blinded by the Light: The Growing Complexity of p53.
    Cell. 2009 May 1;137(3):413-31 PMID: 19410540
  28. Role for the p53 homologue p73 in E2F-1-induced apoptosis.
    Nature. 2000 Oct 5;407(6804):645-8 PMID: 11034215
  29. DeltaNp63alpha levels correlate with clinical tumor response to cisplatin.
    Cell Cycle. 2005 Oct;4(10):1313-5 PMID: 16123597
  30. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis.
    Cancer Cell. 2003 Apr;3(4):387-402 PMID: 12726864
  31. The Delta Np63 alpha phosphoprotein binds the p21 and 14-3-3 sigma promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Wells syndrome-derived mutations.
    Mol Cell Biol. 2003 Apr;23(7):2264-76 PMID: 12640112
  32. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage.
    Nature. 1999 Jun 24;399(6738):806-9 PMID: 10391249
  33. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development.
    Nature. 1999 Apr 22;398(6729):714-8 PMID: 10227294
  34. WW domain-containing E3 ubiquitin protein ligase 1 targets p63 transcription factor for ubiquitin-mediated proteasomal degradation and regulates apoptosis.
    Cell Death Differ. 2008 Dec;15(12):1941-51 PMID: 18806757
  35. Differential expression of p53 gene family members p63 and p73 in head and neck squamous tumorigenesis.
    Hum Pathol. 2002 Feb;33(2):158-64 PMID: 11957139
  36. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers.
    J Clin Invest. 2007 May;117(5):1370-80 PMID: 17446929
  37. TP53 mutations and survival in squamous-cell carcinoma of the head and neck.
    N Engl J Med. 2007 Dec 20;357(25):2552-61 PMID: 18094376
  38. On the shoulders of giants: p63, p73 and the rise of p53.
    Trends Genet. 2002 Feb;18(2):90-5 PMID: 11818141
  39. Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome.
    Cell. 1999 Oct 15;99(2):143-53 PMID: 10535733
  40. Conformational stability and activity of p73 require a second helix in the tetramerization domain.
    Cell Death Differ. 2009 Dec;16(12):1582-9 PMID: 19763140
  41. AIS is an oncogene amplified in squamous cell carcinoma.
    Proc Natl Acad Sci U S A. 2000 May 9;97(10):5462-7 PMID: 10805802
  42. The p53 family protein p73 provides new insights into cancer chemosensitivity and targeting.
    Clin Cancer Res. 2009 Nov 1;15(21):6495-502 PMID: 19861456
  43. A gene signature-based approach identifies mTOR as a regulator of p73.
    Mol Cell Biol. 2008 Oct;28(19):5951-64 PMID: 18678646
  44. A microRNA component of the p53 tumour suppressor network.
    Nature. 2007 Jun 28;447(7148):1130-4 PMID: 17554337
  45. A uniform system for microRNA annotation.
    RNA. 2003 Mar;9(3):277-9 PMID: 12592000
  46. Isoform-specific p73 knockout mice reveal a novel role for delta Np73 in the DNA damage response pathway.
    Genes Dev. 2010 Mar 15;24(6):549-60 PMID: 20194434
  47. REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species.
    Mol Cell. 2002 Nov;10(5):995-1005 PMID: 12453409
  48. Ubiquitin and ubiquitin-like modifications of the p53 family.
    Neoplasia. 2006 Aug;8(8):655-66 PMID: 16925948
  49. p63 deficiency activates a program of cellular senescence and leads to accelerated aging.
    Genes Dev. 2005 Sep 1;19(17):1986-99 PMID: 16107615
  50. Restoration of p53 to limit tumor growth.
    Curr Opin Oncol. 2008 Jan;20(1):90-6 PMID: 18043262
Article Info
Journal
The Journal of clinical investigation
Abbr.
J Clin Invest
ISSN
1558-8238
Published
2011-02-00
Pages
809-20
Language
English
Region
United States
NLM ID
7802877
PMCID
PMC3026726
Subset
IM
Grants
NIDCR NIH HHS · K08 DE020139 · United States
NIDCR NIH HHS · R01 DE015945 · United States
NIDCR NIH HHS · R01 DE-015945 · United States
NIDCR NIH HHS · K08 DE-020139 · United States
Corrections
ErratumIn
-
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com